Zou Chang, Zhao Pan, Xiao Zhangang, Han Xianghua, Fu Fan, Fu Li
Clinical Medical Research Center, The Second Clinical College of Jinan University, Shenzhen People's Hospital, Shenzhen, China.
Research Institute of Shenzhen Hornetcorn biotechnology, Shenzhen, China.
Oncotarget. 2017 Jan 31;8(5):8900-8909. doi: 10.18632/oncotarget.13051.
γδ T cells are one of the three immune cell types that express antigen receptors. They contribute to lymphoid antitumor surveillance and bridge the gap between innate and adaptive immunity. γδ T cells have the capacity of secreting abundant cytokines and exerting potent cytotoxicity against a wide range of cancer cells. γδ T cells exhibit important roles in immune-surveillance and immune defense against tumors and have become attractive effector cells for cancer immunotherapy. γδ T cells mediate anti-tumor therapy mainly by secreting pro-apoptotic molecules and inflammatory cytokines, or through a TCR-dependent pathway. Recently, γδ T cells are making their way into clinical trials. Some clinical trials demonstrated that γδ T cell-based immunotherapy is well tolerated and efficient. Despite the advantages that could be exploited, there are obstacles have to be addressed for the development of γδ T cell immunotherapies. Future direction for immunotherapy using γδ T cells should focus on overcoming the side effects of γδ T cells and exploring better antigens that help stimulating γδ T cell expansion in vitro.
γδ T细胞是表达抗原受体的三种免疫细胞类型之一。它们有助于淋巴样抗肿瘤监测，并在固有免疫和适应性免疫之间架起桥梁。γδ T细胞具有分泌大量细胞因子的能力，并对多种癌细胞发挥强大的细胞毒性作用。γδ T细胞在肿瘤免疫监测和免疫防御中发挥重要作用，已成为癌症免疫治疗中具有吸引力的效应细胞。γδ T细胞主要通过分泌促凋亡分子和炎性细胞因子，或通过TCR依赖性途径介导抗肿瘤治疗。最近，γδ T细胞正在进入临床试验。一些临床试验表明，基于γδ T细胞的免疫疗法耐受性良好且有效。尽管有可利用的优势，但γδ T细胞免疫疗法的发展仍有一些障碍需要解决。使用γδ T细胞进行免疫治疗的未来方向应集中在克服γδ T细胞的副作用，并探索能在体外更好地刺激γδ T细胞扩增的抗原。
